Anti-PF4/heparin antibody formation postorthopedic surgery thromboprophylaxis: the role of non-drug risk factors and evidence for a stoichiometry-based model of immunization
- PMID: 20050998
- DOI: 10.1111/j.1538-7836.2009.03735.x
Anti-PF4/heparin antibody formation postorthopedic surgery thromboprophylaxis: the role of non-drug risk factors and evidence for a stoichiometry-based model of immunization
Abstract
Background: Heparin-induced thrombocytopenia is an antibody-mediated disorder exhibiting variable frequency in different clinical settings. Antibodies recognize PF4/heparin complexes formed at optimal stoichiometric molar ratios.
Objective: To identify clinical factors influencing risk of anti-PF4/heparin immunization.
Patients/methods: We performed observational studies and exploratory analyses of the frequency of anti-PF4/heparin antibody formation in 6324 patients who received enoxaparin or fondaparinux in four randomized controlled trials of postorthopedic surgery thromboprophylaxis. Variables included surgery type (knee vs. hip), timing of first anticoagulant dose (pre- vs. postsurgery), circumstances of surgery (elective vs. hip fracture), anticoagulant (enoxaparin vs. fondaparinux) and body-mass index (BMI). We applied a stoichiometry-based model that predicts immunization risk based on expected differences in PF4/anticoagulant ratios in different settings, and specifically used this model to predict the effect of increasing BMI quartiles upon relative risk (RR) of immunization for fondaparinux vs. enoxaparin.
Results: Anti-PF4/heparin immunization was more frequent after knee vs. hip surgery (particularly for enoxaparin), and when enoxaparin was given post- rather than pre-elective surgery; however, the opposite occurred with hip fracture surgery, that is, antibody formation was more frequent when enoxaparin or fondaparinux was given presurgery. The RR of immunization for fondaparinux vs. enoxaparin decreased significantly for increasing BMI quartiles, an effect predominantly because of increasing immunization with enoxaparin at increasing BMI quartiles.
Conclusions: Several non-drug factors--including type and circumstances of surgery, timing of first anticoagulant dose and BMI--influence risk of anti-PF4/heparin antibody formation, consistent with a stoichiometry-based immunization model of PF4 and anticoagulant ratios occurring during the early peri-operative period.
Similar articles
-
Anti-PF4/heparin antibodies and venous graft occlusion in postcoronary artery bypass surgery patients randomized to postoperative unfractionated heparin or fondaparinux thromboprophylaxis.J Thromb Haemost. 2013 Feb;11(2):253-60. doi: 10.1111/jth.12098. J Thromb Haemost. 2013. PMID: 23216710 Clinical Trial.
-
Anti-platelet factor 4/heparin antibodies in orthopedic surgery patients receiving antithrombotic prophylaxis with fondaparinux or enoxaparin.Blood. 2005 Dec 1;106(12):3791-6. doi: 10.1182/blood-2005-05-1938. Epub 2005 Aug 18. Blood. 2005. PMID: 16109780 Free PMC article. Clinical Trial.
-
Heparin-induced thrombocytopenia: a stoichiometry-based model to explain the differing immunogenicities of unfractionated heparin, low-molecular-weight heparin, and fondaparinux in different clinical settings.Thromb Res. 2008;122(2):211-20. doi: 10.1016/j.thromres.2007.11.007. Epub 2008 Feb 8. Thromb Res. 2008. PMID: 18262226
-
Emerging options for thromboprophylaxis after orthopedic surgery: a review of clinical data.Pharmacotherapy. 2004 Jul;24(7 Pt 2):66S-72S. doi: 10.1592/phco.24.10.66s.36117. Pharmacotherapy. 2004. PMID: 15317401 Review.
-
Fondaparinux: does it cause HIT? Can it treat HIT?Expert Rev Hematol. 2010 Oct;3(5):567-81. doi: 10.1586/ehm.10.54. Expert Rev Hematol. 2010. PMID: 21083474 Review.
Cited by
-
Heparin Induced Thrombocytopenia for the Perioperative and Critical Care Clinician.Curr Anesthesiol Rep. 2020;10(4):501-511. doi: 10.1007/s40140-020-00405-6. Epub 2020 Aug 29. Curr Anesthesiol Rep. 2020. PMID: 32904403 Free PMC article. Review.
-
Emphasis on the Role of PF4 in the Incidence, Pathophysiology and Treatment of Heparin Induced Thrombocytopenia.Thromb J. 2013 Apr 5;11(1):7. doi: 10.1186/1477-9560-11-7. Thromb J. 2013. PMID: 23561460 Free PMC article.
-
A Simple Clinical Pre-procedure Risk Model for Predicting Thrombocytopenia Associated With Periprocedural Use of Tirofiban in Patients Undergoing Percutaneous Coronary Intervention.Front Pharmacol. 2018 Dec 10;9:1456. doi: 10.3389/fphar.2018.01456. eCollection 2018. Front Pharmacol. 2018. PMID: 30618750 Free PMC article.
-
IgG-class anti-PF4/heparin antibodies and symptomatic DVT in orthopedic surgery patients receiving different anti-thromboembolic prophylaxis therapeutics.BMC Musculoskelet Disord. 2011 Jan 24;12:22. doi: 10.1186/1471-2474-12-22. BMC Musculoskelet Disord. 2011. PMID: 21261941 Free PMC article.
-
Mechanical prophylaxis is a heparin-independent risk for anti-platelet factor 4/heparin antibody formation after orthopedic surgery.Blood. 2016 Feb 25;127(8):1036-43. doi: 10.1182/blood-2015-06-651620. Epub 2015 Dec 9. Blood. 2016. PMID: 26659923 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous